Notable
TiTRE · Tirzepatide Titration to Reduce Side Effects · Obesity
Primary endpoint(s) modified
Dasman Diabetes InstituteNot applicable NCT07574723 Registry history of NCT07574723 on ClinicalTrials.gov (opens the registry)
1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.
Primary endpoint(s) modified
Dasman Diabetes InstituteNot applicable NCT07574723 Registry history of NCT07574723 on ClinicalTrials.gov (opens the registry)
| Phase 2 | 1 | |
| Phase 4 | 2 |
Diabetes (6) · Type 1 Diabetes (5) · Obesity (3) · Type 2 Diabetes (2) · NASH / MASH (1)